Artificial Intelligence | Machine Learning | Natural Language Processing Transition Bio | Our Proprietary Drug Discovery Platform


Enterprise, Biomolecular Condensate Analysis, Microluidics, Drug Discovery Cambridge, Massachusetts , United States

Transition Bio

Artificial Intelligence | Machine Learning | Natural Language Processing


Transition Bio | Our Proprietary Drug Discovery Platform

Transition Bio

Biomolecular Condensate Analysis, Microluidics, Drug Discovery


Cambridge, Massachusetts , United States

Transition Bio has leveraged the experience of world-leading experts in microfluidics, cell imaging, and machine learning to establish a one-of-a-kind technology platform to revolutionize condensate drug discovery. We bring together science and technology to create novel therapeutics. Transition Bio combines first-of-its-kind microfluidic tools, cellular assays, and machine learning to explore chemical space – in vitro, in vivo & in silico – to discover new therapies for diseases driven by biomolecular condensates. 

Inside all our cells, many of the reactions that keep us alive happen within biomolecular condensates, non-membrane-bound structures containing proteins and genetic material.  Diseases can arise when these structures go awry.  Currently, there are no approved therapies targeted to specifically address these problems. Our platform helps us to more rapidly understand the properties of condensates compared with traditional screening methods, ultimately enabling a more efficient design of targeted therapeutics. 

We employ a multidimensional, high-throughput approach to studying the modulation of biomolecular condensates. Using our one-of-a-kind screening platform, we generate extensive behavioral datasets on the mechanisms of condensate modulation, which until now have been unavailable. We combine our cellular assays with state-of-the-art imaging and analytical techniques to unravel the effects of condensate modulators in bespoke cell lines and discover how molecules affect condensate formation at the cellular level. We study condensate composition and determine how condensates affect key cellular processes. This deep level of understanding enables us to determine the best condensate targets and the most appropriate interventions. Incorporating our unique datasets generated from our platform, we apply machine learning for target prediction and in-silico drug discovery.&a

 

B2B

26 to 50

N/A

N/A

Scaling Up

2020

 
 

Biotechnology

Condensomics

Increase Efficiency
Increase Productivity

 
 

Service

Yes

Active

 
 

   Machine Learning
   Natural Language Processing
   Automated Planning and Search


Drug Discovery

Drug Discovery


Image

Image

Video

Video

Structured

Structured

 

   Software


Python

Python

Pytorch

Pytorch

Keras

Keras


Machine Learning Algorithm

Machine Learning Algorithm

Deep Learning Algorithm

Deep Learning Algorithm

 
 

5

1

$50M

Company was founded 2020 and it took almost 2 years (Jun 2022) to raise first external round

 
 

Date

Round

$ Raised

Investors

06/02/2022

Series A

$50M

Northpond Ventures, Taiho Ventures, Bristol Myers Squibb, Lifeforce Capital, Magnetic Ventures

Date : 06/02/2022

Round: Series A

$ Raised: $50M

Investors: Northpond Ventures, Taiho Ventures, Bristol Myers Squibb, Lifeforce Capital, Magnetic Ventures

 

Investors

Interested in researching Transition Bio?

We have plenty of data and we can help. Our deal sourcing platform can help you perform more research about Transition Bio

Request a Demo - Deal Souring Platform

 
Kadi Saar

Kadi Saar
Technical Co-Founder & Director, Machine Learning

Gregory Miller

Gregory Miller
Chief Executive Officer

Martin Kulander

Martin Kulander
Chief Operating Officer

Samuel Cohen

Samuel Cohen
Board Member & Co-Founder

 
 

Potential Customers

Interested in what they do or partnership?

Learn more about how they work

Schedule a Call w/ Transition Bio